TP53 and gastric cancer: In addition to the antitumor effects of atractylenolide I on lung cancer cells, ovarian cancer cells, and leukemia cells in vitro experiments (62–64), in vivo the results of the study show that Atractylenolide 1 significantly inhibited the tumor body of SGC-7901 gastric cancer cells in BALB/C nude mice with loaded mice by increasing the expression of Bax, cleaved caspase-3, and p53, and decreasing the manifestation of Bcl-2 proliferation (65).